Xencor, Inc Asset Impairment Charges
Xencor, Inc (XNCR) reported Asset Impairment Charges of $797.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2026-08-05
- Xencor, Inc asset impairment charges for the quarter ending 2026-06-30 was $797.00K, a 57.10% decline year-over-year.
- Xencor, Inc asset impairment charges for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Xencor, Inc asset impairment charges for the quarter ending 2025-12-31 was $881.00K.
- Xencor, Inc asset impairment charges for the quarter ending 2025-09-30 was $1.56M.
- Xencor, Inc asset impairment charges for fiscal 2025 was $9.17M, a 55.12% decline from fiscal 2024.
- Xencor, Inc asset impairment charges for fiscal 2024 was $20.43M.
- Xencor, Inc asset impairment charges for fiscal 2023 was $0.00.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 6 month | Asset Impairment Charges 9 month | Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $797.00K 10-Q · filed 2026-08-05 | $797.00K 10-Q · filed 2026-08-05 | $1.68M derived: sum of 3 quarters · filed 2026-08-05 | $3.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $881.00K derived: sum of 2 quarters · filed 2026-05-06 | $2.45M derived: sum of 3 quarters · filed 2026-05-06 | $4.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $881.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.45M derived: sum of 2 quarters · filed 2026-02-25 | $4.30M derived: sum of 3 quarters · filed 2026-08-05 | $9.17M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.56M 10-Q · filed 2025-11-05 | $3.42M derived: sum of 2 quarters · filed 2026-08-05 | $8.29M 10-Q · filed 2025-11-05 | $8.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.86M 10-Q · filed 2026-08-05 | $6.72M 10-Q · filed 2026-08-05 | $6.72M derived: sum of 3 quarters · filed 2026-08-05 | $6.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.87M 10-Q · filed 2026-05-06 | $4.87M derived: sum of 2 quarters · filed 2026-05-06 | $4.87M derived: sum of 3 quarters · filed 2026-05-06 | $4.64M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | -$220.00K derived: sum of 3 quarters · filed 2026-02-25 | $20.43M 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | -$220.00K derived: sum of 2 quarters · filed 2025-11-05 | $20.43M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$220.00K 10-Q · filed 2025-08-06 | $20.43M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $20.65M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |